Acquired by Currax Pharmaceuticals
Industries BiotechnologyHealth CarePharmaceuticalHeadquarters Regions Greater Houston Area, Southern US Closed Date May 1, 2019 Founded Date 1997 Operating Status Closed Last Funding Type Post-IPO Debt
Stock Symbol NASDAQ:PTX Company Type For Profit
Phone Number 800-793-2145
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper
respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis. The Company promotes its products through a sales and marketing organization with approximately 55 sales representatives, primarily in highly populated states, targeting pediatric and high-prescribing physicians that are in the top decile of physicians that prescribe its products. The Company’s current operating plan focuses on maximizing sales of its existing product portfolio. In addition, Pernix plans to accelerate growth by launching new products, line extensions, and new formulations and by acquiring and licensing approved products.
Transaction Name Pernix Therapeutics acquired by Currax PharmaceuticalsAcquired by Currax PharmaceuticalsAnnounced Date May 1, 2019